EmilChuangMD

PubMed

• 10 citations
  Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2/D3 receptor antagonist, in patients with gastroparesis
  Braden Kuo, Cecilia Scimia, George Dukes, Wenwen Zhang, Saurabh Gupta, Chunlin Chen, Emil Chuang, Michael Camilleri> ;Alimentary Pharmacology & Therapeutics. 2021 Jun 20
• 53 citations
  Challenges in IBD Research: Environmental Triggers.
  Shuk-Mei Ho, James D. Lewis, Emeran A. Mayer, Charles N. Bernstein, Scott E. Plevy, Emil Chuang, Stephen M. Rappaport, Kenneth Croitoru, Joshua R. Korzenik, Jeffrey P....> ;Inflammatory Bowel Diseases. 2019 May 16
• 12 citations
  Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women wit...
  Kevin W Olden, William D. Chey, Reshma Shringarpure, Jean Paul Nicandro, Emil Chuang, David L. Earnest> ;Current Medical Research and Opinion. 2019 Mar 1
• 21 citations
  Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint:
  Brian E. Lacy, Jean Paul Nicandro, Emil Chuang, David L. Earnest> ;Therapeutic Advances in Gastroenterology. 2018 May 8
• 32 citations
  Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD.
  Naamah L. Zitomersky, Benjamin J. Atkinson, Kerri Ann Fournier, Paul Mitchell, Julia Bender Stern, Michael C. Butler, Lori A. Ashworth, Scott Hauenstein, Linda Heiner,...> ;Inflammatory Bowel Diseases. 2015 Feb 1
• 42 citations
  A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.
  Kenneth Tong, Jean Paul Nicandro, Reshma Shringarpure, Emil Chuang, Lin Chang> ;Therapeutic Advances in Gastroenterology. 2013 Jun 18
• 67 citations
  Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay
  S. T. Wang, Scott Hauenstein, Linda Ohrmund, Reshma Shringarpure, Jared Salbato, Rukmini Reddy, Kevin McCowen, Shawn Shah, Steven Lockton, Emil Chuang, Sharat Singh> ;Journal of Pharmaceutical and Biomedical Analysis. 2013 May 5
• 89 citations
  Combined Serological, Genetic, and Inflammatory Markers Differentiate Non-IBD, Crohn's Disease, and Ulcerative Colitis Patients
  Scott E. Plevy, Mark S. Silverberg, Steven Lockton, Thomas P. Stockfisch, Lisa J. Croner, Jordan Stachelski, Michelle Brown, Cheryl Triggs, Emil Chuang, Fred Princen, ...> ;Inflammatory Bowel Diseases. 2013 May 1
• 21 citations
  Biomedicines to reduce inflammation but not viral load in chronic HCV--what's the sense?
  Emil Chuang, Alfred Del Vecchio, Steve Smolinski, Xiao-Yu Song, Robert T. Sarisky> ;Trends in Biotechnology. 2004 Oct 1
• Join now to see all